J&J lines up its 4-in-1 HIV pill for FDA behind rivals from Gilead, GSK
A couple of months after posting positive late-stage data for its quadruplet-in-one-pill for quelling HIV, J&J says it’s filed a marketing application with the FDA ahead of a planned marketing campaign.
Cocktail therapies have proven highly effective at keeping HIV at bay, but the big players in the market — like Gilead, GSK and J&J — have all been hustling along to prove that their combos can do the job while promising to improve adherence to drug regimens and heighten their consistency.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
